CleanCap Technology: Leading the way in mRNA™
CleanCap technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low capping efficiencies (mCAP/ARCA) or high enzyme costs that are associated with traditional capping methods.
CleanCap is efficient, elicits high yields of capped mRNA, and provides a mRNA 5’ cap structure. CleanCap is available in a variety of structures with specific initiation sequences. The newest analog to the CleanCap portfolio is CleanCap AU, optimized for self-amplifying mRNA vaccine development. Our robust suite of CleanCap capping strategies is available for endless application possibilities.
Submit your contact information to receive access to technical articles, brochures, and more.